Management of advanced and/or metastatic carcinoid tumors: historical perspectives and emerging therapies

Bibliography

• Rehfeld JF. The new biology of gastrointestinal hormones. Physiol Rev 1998;78:1087-108
   PubMed Web of Science ®Google Scholar
• Townsend A, Price T, Yeend S, et al. Metastatic carcinoid tumor: changing patterns of care over two decades. J Clin Gastroenterol 2009;44(3):195-9
   Google Scholar
• Modlin IM, Shapiro KD, Kidd M, et al. Siegfried Oberndorfer and the evolution of carcinoid disease. Arch Surg 2007;187-97
   PubMedGoogle Scholar
• Bosman F, Carneiro F, Hruban R, Theise N. editors. WHO classification of tumors of the digestive system. IARC Press, Lyon, France; 2010
   Google Scholar
• Zuetenhorst JM, Taal BG. Metastatic carcinoid tumors: a clinical review. Oncologist 2005;10:123-31
   PubMed Web of Science ®Google Scholar
• Hemminki K, Li X. Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. Cancer 2001;92:2204-10
   PubMed Web of Science ®Google Scholar
• Quaedvlieg PF, Visser O, Lamers CB, et al. Epidemiology and survival of patients with carcinoid disease in The Netherlands. An epidemiological study with 2391 patients. Ann Oncol 2001;12:1295-300
   PubMed Web of Science ®Google Scholar
• Oberg K. Carcinoid tumors: current concepts in diagnosis and treatment. Oncologist 1998;3:339-45
   PubMedGoogle Scholar
• Ghevariya V, Malieckal A, Ghevariya N, et al. Carcinoid tumors of the gastrointestinal tract. South Med J 2009;102:1032-40
   PubMedGoogle Scholar
• Dong Q, Debelenko LV, Chandrasekharappa SC, et al. Loss of heterozygosity at 11q13: analysis of pituitary tumors, lung carcinoids, lipomas and other uncommon tumors in subjects with familial multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 1997;82:1416-20
   PubMed Web of Science ®Google Scholar
• Modlin IM, Latich I, Kidd M, et al. Therapeutic options for gastrointestinal carcinoids. Clin Gastroenterol Hepatol 2006;4:526-47
   PubMed Web of Science ®Google Scholar
• Warner TF, O'Reilly G, Lee GA. Mesenteric occlusive lesion and ileal carcinoids. Cancer 1979;44:758-62
   PubMed Web of Science ®Google Scholar
• Sutton R, Doran HE, Williams EM, et al. Surgery for midgut carcinoid. Endocr Relat Cancer 2003;10:469-81
   PubMedGoogle Scholar
• Ramage JK, Davies AHG, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine carcinoids. Clin Gastroenterol Hepatol 2006;4:526-47
   PubMedGoogle Scholar
• Robiolio PA, Rigolin VH, Wilson JS, et al. Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Cicrulation 1995;92:790-5
   PubMedGoogle Scholar
• Lundin L, Norheim I, Landelius J, et al. Carcinoid heart disease: relationship of circulating vasoactive substances to ultrasound-detectable cardiac abnormalities. Circulation 1988;77:264-9
   PubMed Web of Science ®Google Scholar
• Ross EM, Roberts WC. The carcinoid syndrome: comparison of 21 necropsy subjects with carcinoid heart disease to 15 necropsy subjects without carcinoid heart disease. Am J Med 1985;79:339-54
   PubMed Web of Science ®Google Scholar
• Taal BG, Hoefnagel CA, Valdes Olmos RA, et al. Combined diagnostic imaging with 131I-metaiodobenzylguanidine and 111In-pentetreotide in carcinoid tumours. Eur J Cancer 1996;32A:1924-32
   PubMed Web of Science ®Google Scholar
• Bajetta E, Ferrari L, Martinetti A, et al. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer 1999;86:858-65
   PubMed Web of Science ®Google Scholar
• Kema IP, Schellings AM, Meiborg G, et al. Influence of a serotonin- and dopamine-rich diet on platelet serotonin content and urinary excretion of biogenic amines and their metabolites. Clin Chem 1992;38:1730-6
   PubMed Web of Science ®Google Scholar
• Meijer WG, Kema IP, Volmer M, et al. Discriminating capacity of indole markers in the diagnosis of carcinoid tumors. Clin Chem 2000;46:1588-96
   PubMed Web of Science ®Google Scholar
• Modlin IM, Pavel M, Kidd M, et al. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther 2010;31:169-88
   PubMed Web of Science ®Google Scholar
• Janson ET, Oberg K. Long-term management of the carcinoid syndrome; treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol 1993;32:225-9
   PubMed Web of Science ®Google Scholar
• Leong WY, Pasieka JL. Regression of metastatic carcinoid tumors with octreotide therapy: two case reports and a review of the literature. J Surg Oncol 2002;79:180-7
   PubMed Web of Science ®Google Scholar
• Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol 2009;27:4656-63
   PubMed Web of Science ®Google Scholar
• Ramanathan RK, Cnaan A, Hahn RG, et al. Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol 2001;12:1139-43
   PubMed Web of Science ®Google Scholar
• Dahan L, Bonnetain F, Rougier P, et al. Phase III trial of chemotherapy using 5-fluorouracil and streptozocin compared with interferon alpha for advanced carcinoid tumors: FNCLCC-FFCD 9710. Endocr Relat Cancer 2009;16:1351-61
   PubMed Web of Science ®Google Scholar
• Moertel CG, Hanley JA. Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin Trials 1979;2:327-34
   PubMedGoogle Scholar
• Sun W, Lipsitz S, Catalano P, et al. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: eastern cooperative oncology group study E1281. J Clin Oncol 2005;23(22):4897-904
   PubMed Web of Science ®Google Scholar
• Oberg K. The action of interferon alpha on human carcinoid tumours. Semin Cancer Biol 1992;3:35-41
   PubMedGoogle Scholar
• Di Bartolomeo M, Bajetta E, Zilembo N, et al. Treatment of carcinoid syndrome with recombinant interferon alpha-2a. Acta Oncol (Madr) 1993;32(2):235-8
   PubMed Web of Science ®Google Scholar
• Bajetta E, Zilembo N, Di Bartolomeo M, et al. Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a: a study by the Italian trials in Medical Oncology Group. Cancer 1993;72(10):3099-105
   PubMedGoogle Scholar
• Oberg K, Alm G. The incidence and clinical significance of antibodies to interferon-alpha in patients with solid tumors. Biotherapy 1997;10:1-5
   PubMedGoogle Scholar
• Ekeblad S, Sundin A, Janson ET, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 2007;13:2986-91
   PubMed Web of Science ®Google Scholar
• Yao JC, Phan A, Hoff PM, et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and peglyated interferon alfa-2b. J Clin Oncol 2008;26(8):1316-23
   PubMed Web of Science ®Google Scholar
• Ng CS, Charnsangavej C, Wei W, et al. Perfusion CT findings in patients with metastatic carcinoid tumors undergoing bevacizumab and interferon therapy. AJR 2011;196:569-76
   PubMedGoogle Scholar
• Kulke MH, Lenz HJ, Meropol JP, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008;26(20):3403-10
   PubMed Web of Science ®Google Scholar
• Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. New Engl J Med 2011;364:514-23
   PubMed Web of Science ®Google Scholar
• Yao JC, Phan A, Chang D, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low-to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008;26:4311-18
   PubMed Web of Science ®Google Scholar
• Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011;378:2005-12
   PubMed Web of Science ®Google Scholar
• Fine R, Fogelman F, Schreibman S. Effective treatment of neuroendocrine tumors with capecitabine and temozolomide. ASCO 2005;Abstract No. 4216
   Google Scholar
• Strosberg JR, Fine RL, Choi J, et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011;117:268-75
   PubMed Web of Science ®Google Scholar
• Chan JA, Stuart K, Earle CC, et al. Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol 2012;30(24):2963-8
   PubMed Web of Science ®Google Scholar
• Kulke MH, Stuart K, Enzinger PC, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006;24:401-6
   PubMed Web of Science ®Google Scholar
• Varker KA, Campbell J, Shah MH. Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors. Cancer Chemother Pharmacol 2008;61:661-8
   PubMed Web of Science ®Google Scholar
• Iyer R, Fetterly G, Lugade A, et al. Sorafenib: a clinical and pharmacologic review. Expert Opin Pharmacother 2010;11:1943-55
   PubMed Web of Science ®Google Scholar
• Hobday T, Rubin J, Holen K, et al. MC044h, a phase II trial of sorafenib in patients with metastatic neuroendocrine tumors (NET): a phase II consortium (P2C) study. 2007 ASCO Annual Meeting. J Clin Oncol 2007;25(18 Suppl 20):4504
   Google Scholar
• Castellano DE, Capdevila J, Salazar R, et al. Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumor: a phase II study of the Spanish neuroendocrine tumor group (GETNE0801). 2011 ASCO Annual Meeting. J Clin Oncol 2011;29(Suppl): abstract 4113
   Google Scholar
• Guilhot F. Indications for imatinib mesylate therapy and clinical management. Oncologist 2004;9:271-81
   PubMed Web of Science ®Google Scholar
• Yao JC, Zhang JX, Rashid A, et al. Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin Cancer Res 2007;13:234-40
   PubMed Web of Science ®Google Scholar